Scotiabank Has Lowered Expectations for Healthpeak Properties (NYSE:DOC) Stock Price

Healthpeak Properties (NYSE:DOC) had its price target dropped by stock analysts at Scotiabank from $24.00 to $23.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “sector outperform” rating on the real estate investment trust’s stock. Scotiabank’s target price indicates a potential upside of 12.55% from the stock’s current price.

DOC has been the subject of a number of other reports. Mizuho reduced their price target on shares of Healthpeak Properties from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Thursday, December 5th. Morgan Stanley upgraded Healthpeak Properties from an “equal weight” rating to an “overweight” rating and set a $25.00 price target on the stock in a report on Wednesday, January 15th. Wedbush reduced their price objective on Healthpeak Properties from $27.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 14th. Robert W. Baird reduced their price objective on Healthpeak Properties from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Tuesday, February 11th. Finally, Wells Fargo & Company reduced their target price on Healthpeak Properties from $23.00 to $22.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $23.92.

Healthpeak Properties Trading Up 1.3 %

DOC stock traded up $0.26 during mid-day trading on Friday, reaching $20.44. 7,268,357 shares of the stock traded hands, compared to its average volume of 4,801,222. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.96. Healthpeak Properties has a 52-week low of $16.49 and a 52-week high of $23.26. The company has a market cap of $14.30 billion, a P/E ratio of 58.39, a P/E/G ratio of 2.17 and a beta of 1.15. The stock’s fifty day moving average is $20.18 and its 200-day moving average is $21.36.

Institutional Trading of Healthpeak Properties

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp acquired a new stake in Healthpeak Properties in the third quarter worth about $1,093,576,000. JPMorgan Chase & Co. lifted its stake in Healthpeak Properties by 23.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 21,561,640 shares of the real estate investment trust’s stock valued at $493,115,000 after acquiring an additional 4,056,931 shares in the last quarter. Geode Capital Management LLC lifted its stake in Healthpeak Properties by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 18,355,772 shares of the real estate investment trust’s stock valued at $371,168,000 after acquiring an additional 638,012 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Healthpeak Properties by 2,113.5% in the 4th quarter. Principal Financial Group Inc. now owns 18,133,812 shares of the real estate investment trust’s stock valued at $367,575,000 after acquiring an additional 17,314,572 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. lifted its stake in Healthpeak Properties by 10.6% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 17,267,917 shares of the real estate investment trust’s stock valued at $350,021,000 after acquiring an additional 1,651,235 shares in the last quarter. 93.57% of the stock is currently owned by institutional investors and hedge funds.

Healthpeak Properties Company Profile

Healthpeak Properties, Inc is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery.